We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Arecor Therapeutics
AT220 European launch marks first Arestat successHUTCHMED
Landmark FDA approval for fruquintinibANGLE
Moving in the right direction to capture growthScancell
Business update and FY23 resultsRedx Pharma
New funds provide runway through 2024 catalystsAvacta
Momentum builds in Diagnostics and TherapeuticsScancell
SCIB1 SCOPE study shows a striking 82% ORRFutura Medical
Significant achievements position MED3000 for successArecor Therapeutics
Growth plans starting to stack upHUTCHMED
Surfing the ‘waves’ towards profitability